Smart insulin dosing system aims to simplify diabetes management

NCT ID NCT07681375

Ongoing Disease control Sponsor: DexCom, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a system that combines a continuous glucose monitor (CGM) with daily insulin dose recommendations for people with type 2 diabetes who are starting basal insulin. Participants wear a Dexcom CGM sensor and receive suggested insulin doses through the DexBasal system, which a physician reviews. The goal is to see if the system is safe and works well for managing blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Basal insulin (DexBasal)
What this could lead to: If successful, this system could help people with type 2 diabetes manage their blood sugar more easily and safely by automating insulin dose adjustments.
What could go wrong: This is a small, early-phase feasibility study, so the system may not work as intended or may not improve outcomes. Risks include low blood sugar (hypoglycemia) and device issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

San Diego Family Care (SDFC)

San Diego, California, 92111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.